「经典型浸润性小叶癌」这一术语定义了性质迥异的乳腺恶性肿瘤
研究基于本机构1996-2019年诊断的560例无微钙化的经典型浸润性小叶癌,按乳腺X线影像生物标志物前瞻性分类并随访至2021年12月31日,另以2600例其他类型无微钙化浸润性乳腺癌为参照。影像生物标志物区分出两个亚组:广泛结构扭曲无中央肿块者长期生存率56%,星状或圆形无钙化肿块(多小于20mm)者长期生存率84%。作者认为同一组织病理学诊断下两种肿瘤的亚 gross 病理与乳腺X线表现及长期结局差异显著,使用同一术语可能对治疗决策产生不利影响。
要点
- 经典型浸润性小叶癌按乳腺X线表现可分为两个亚组,长期生存率分别为56%和84%。
- 广泛结构扭曲无中央肿块者预后较差,星状或圆形无钙化肿块(多小于20mm)者预后较好。
- 同一组织病理学诊断下影像表现与结局差异显著,提示需区分对待。
核心结论
- 具有相同组织病理学诊断「经典型浸润性小叶癌」的两种乳腺恶性肿瘤,其亚 gross 病理与乳腺X线表现(影像生物标志物)存在显著差异,长期结局差异更大,使用同一术语描述这两种独立实体可能对治疗决策产生不利影响。
研究设计与样本
- 本机构1996-2019年诊断的无微钙化经典型浸润性小叶癌560例,按乳腺X线影像生物标志物前瞻性分类并随访至2021年12月31日;另以2600例无微钙化的其他类型浸润性乳腺癌为参照组;详细组织病理学分析采用大尺寸(10x8 cm)薄切片技术及HE、E-cadherin、细胞角蛋白CK 5/6、跨膜糖蛋白CD44和抗肌动蛋白或抗平滑肌肌球蛋白重链染色。
关键影像表现/征象
- 一个亚组表现为广泛结构扭曲、无中央肿瘤肿块,占据小叶外间质。
- 另一亚组形成星状或圆形无钙化肿瘤肿块,通常小于20 mm,似乎起源于小叶内间质。
诊断标准与关键数值
- 广泛结构扭曲无中央肿块亚组的长期生存率为56%。
- 星状或圆形无钙化肿块(通常小于20 mm)亚组的长期生存率为84%。
临床应用与阅片要点
- 阅片时需注意经典型浸润性小叶癌可表现为广泛结构扭曲无中央肿块或星状/圆形无钙化肿块两种影像模式,两者长期生存率分别为56%和84%。
- 作者建议对这一影像生物标志物可区分的两种独立实体使用特定术语,因使用同一术语可能对治疗决策产生不利影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To describe in detail the special features of a previously unappreciated "classic invasive lobular carcinoma" which is confined to the terminal ductal lobular units (TDLUs) and differs considerably from the extensive classic invasive lobular carcinoma, and to suggest specific terminology.
METHOD: All invasive breast cancer cases without associated microcalcifications diagnosed in our Institution with the histopathologic diagnosis of classic invasive lobular carcinoma during the years 1996-2019 (n = 560) formed the basis of this study. The cases were prospectively classified according to their imaging biomarkers (mammographic features) and followed up to Dec 31, 2021, to determine long-term patient outcome. An additional 2600 invasive breast cancer cases (diagnosed other than invasive lobular carcinoma) without associated microcalcifications served as a reference group. Detailed histopathologic analysis used large format (10x8 cm) thin section technique and staining methods including hematoxylin-eosin (H&E), E-cadherin, cytokeratin CK 5/6, a transmembrane glycoprotein (CD44) and anti-actin or anti-smooth muscle myosin heavy chain.
RESULTS: The imaging biomarkers differentiated two separate disease subgroups, having the same histopathologic diagnosis, classic invasive lobular carcinoma. One of these has the imaging biomarker of extensive architectural distortion with no central tumour mass, occupies the extralobular mesenchyme and has a long-term survival of 56%. The other subgroup forms stellate or circular non-calcified tumour masses usually smaller than 20 mm, which appear to arise in the intralobular mesenchyme, and has a significantly better long-term survival of 84%.
CONCLUSIONS: There is a striking difference between the subgross histopathology and the mammographic appearance (imaging biomarkers) of two breast malignancies having the same histopathologic diagnosis, "classic invasive lobular carcinoma". The large difference in the long-term outcome of these two tumour types is even more striking. Using the same specific term, "classic invasive lobular carcinoma", to describe these two separate entities can adversely affect management decisions.
引用
- Tabár L, Dean PB, Ming-Fang Yen A, et al. The term "classic invasive lobular carcinoma" of the breast defines breast malignancies of vastly different nature. Eur J Radiol. 2023. PMID: 37813006. doi:10.1016/j.ejrad.2023.111119
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。